We conducted a comprehensive analysis and found 27 circulating microRNAs that were significantly different in people with ME/CFS and POTS (postural orthostatic tachycardia syndrome) compared to those with ME/CFS alone or POTS alone.
Cognitive assessments using BrainCheck enabled the stratification of ME/CFS patients into three distinct clusters based on cognitive response.
Our recent study about a hormone called FGF-21 in the blood can help explain why people with ME/CFS, FM, or both experience different symptoms and levels of brain fog. Instead of focusing only on diagnosis, we grouped patients by low, normal, or high FGF-21 levels and discovered clear patterns—like worse fatigue and thinking problems in those with low levels. This matters because it shows that FGF-21 could be used to personalize care, helping doctors better understand each patient’s condition and choose treatments that match their unique biology.
Multiple manuscripts on this work are in preparation. Two have been published:
STUDY HYPOTHESIS AND DESCRIPTION
Our study will couple a deep phenotyping
characterization of ME/CFS patients to the
development of cellular and animal models
for repurposing current drugs to accelerate
the proof-of-concept of different therapeutic
interventions for ME/CFS. Indeed, precision
medicine is essential to address the clinical
complexity of ME/CFS and to identify the
best therapeutic options to cure ME/CFS.

OBJECTIVES